Vaxfectin™ enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines

Vaccine

Volumn 24, Issue 11, 2006, Pages 1921-1927

  Sedegah, Martha ^a   Rogers, William O ^a,c   Belmonte, Arnel ^a   Belmonte, Maria ^a   Banania, Glenna ^a   Patterson, Noelle ^a   Ferrari, Marilyn ^b   Kaslow, David C ^b   Carucci, Daniel J ^a   Richie, Thomas L ^a   Doolan, Denise L ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b VICAL INC   (United States)

^c US Naval Medical Research Unit No 2 Jakarta   (Indonesia)

Author keywords

Malaria; Plasmid DNA (pDNA) vaccines; T lymphocytes

Indexed keywords

1,2 DIPHYTANOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; LIPID; MALARIA VACCINE; N (3 AMINOPROPYL) N,N DIMETHYL 2,3 BIS(9 TETRADECENYLOXY) 1 PROPANAMINIUM BROMIDE; PLASMID DNA; UNCLASSIFIED DRUG; VAXFECTIN; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; IMMUNOLOGICAL ADJUVANT; PHOSPHATIDYLETHANOLAMINE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SCREENING; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; LOW DRUG DOSE; MALARIA; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PLASMODIUM YOELII; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE; VACCINIA VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNIZATION, SECONDARY; LYMPHOCYTES; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PHOSPHATIDYLETHANOLAMINES; PLASMODIUM YOELII; PROTOZOAN PROTEINS; VACCINES, DNA; VACCINIA VIRUS;

EID: 32544448799     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.10.041     Document Type: Article

References (26)

1. P. Pancholi, D.H. Lee, Q. Liu, C. Tackney, P. Taylor, and M. Perkus DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee Hepatology 33 2 2001 448 454
2. H.L. Robinson, D.C. Montefiori, R.P. Johnson, K.H. Manson, M.L. Kalish, and J.D. Lifson Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations Nat Med 5 5 1999 526 534
3. N.J. Sullivan, A. Sanchez, P.E. Rollin, Z.Y. Yang, and G.J. Nabel Development of a preventive vaccine for Ebola virus infection in primates Nature 408 6812 2000 605 609
4. M. Mwau, I. Cebere, J. Sutton, P. Chikoti, N. Winstone, and E.G. Wee A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans J Gen Virol 85 Pt 4 2004 911 919
5. V.S. Moorthy, E.B. Imoukhuede, S. Keating, M. Pinder, D. Webster, and M.A. Skinner Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men J Infect Dis 189 12 2004 2213 2219
6. S.J. McConkey, W.H. Reece, V.S. Moorthy, D. Webster, S. Dunachie, and G. Butcher Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans Nat Med 9 6 2003 729 735
7. D.P. Webster, S. Dunachie, J.M. Vuola, T. Berthoud, S. Keating, and S.M. Laidlaw Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara Proc Natl Acad Sci USA 102 13 2005 4836 4841
8. R. Wang, D.L. Doolan, T.P. Le, R.C. Hedstrom, K.M. Coonan, and Y. Charoenvit Induction of antigen-specific cytotoxic T-lymphocytes in humans by a malaria DNA vaccine Science 282 5388 1998 476 480
9. M. Pavlenko, A.K. Roos, A. Lundqvist, A. Palmborg, A.M. Miller, and V. Ozenci A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer Br J Cancer 91 4 2004 688 694
10. J. Hartikka, V. Bozoukova, M. Ferrari, L. Sukhu, J. Enas, and M. Sawdey Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens Vaccine 19 15-16 2001 1911 1923
11. L. Reyes, J. Hartikka, V. Bozoukova, L. Sukhu, W. Nishioka, and G. Singh Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization Vaccine 19 27 2001 3778 3786
12. C. Nukuzuma, N. Ajiro, C.J. Wheeler, and E. Konishi Enhancing effect of vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice Viral Immunol 16 2 2003 183 189
13. V. Sankar, L. Baccaglini, M. Sawdey, C.J. Wheeler, S.R. Pillemer, and B.J. Baum Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses Oral Dis 8 6 2002 275 281
14. S. D'Souza, V. Rosseels, O. Denis, A. Tanghe, N. De Smet, and F. Jurion Improved tuberculosis DNA vaccines by formulation in cationic lipids Infect Immun 70 7 2002 3681 3688
15. C.P. Locher, S.A. Witt, B.M. Ashlock, P. Polacino, S.L. Hu, and S. Shiboski Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection Vaccine 22 17-18 2004 2261 2272
16. G. Hermanson, V. Whitlow, S. Parker, K. Tonsky, D. Rusalov, and M. Ferrari A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores Proc Natl Acad Sci USA 101 37 2004 13601 13606
17. E. Galanis, E.M. Hersh, A.T. Stopeck, R. Gonzalez, P. Burch, and C. Spier Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience J Clin Oncol 17 10 1999 3313 3323
18. A.T. Stopeck, A. Jones, E.M. Hersh, J.A. Thompson, D.M. Finucane, and J.C. Gutheil Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma Clin Cancer Res 7 8 2001 2285 2291
19. L. Fischer, J.P. Tronel, J. Minke, S. Barzu, P. Baudu, and J.C. Audonnet Vaccination of puppies with a lipid-formulated plasmid vaccine protects against a severe canine distemper virus challenge Vaccine 21 11-12 2003 1099 1102
20. L. Fischer, J. Minke, N. Dufay, P. Baudu, and J.C. Audonnet Rabies DNA vaccine in the horse: strategies to improve serological responses Vaccine 21 31 2003 4593 4596
21. M. Belmonte, T.R. Jones, M. Lu, R. Arcilla, T. Smalls, and A. Belmonte The infectivity of Plasmodium yoelii in different strains of mice J Parasitol 89 3 2003 602 603
22. M. Sedegah, T.R. Jones, M. Kaur, R.C. Hedstrom, P. Hobart, and J.A. Tine Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine Proc Natl Acad Sci USA 95 13 1998 7648 7653
23. M. Sedegah, R. Hedstrom, P. Hobart, and S.L. Hoffman Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein Proc Natl Acad Sci USA 91 1994 9866 9870
24. H.M. Horton, O. Dorigo, P. Hernandez, D. Anderson, J.S. Berek, and S.E. Parker IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile J Immunol 163 12 1999 6378 6385
25. R. Wang, J. Epstein, F.M. Baraceros, E.J. Gorak, Y. Charoenvit, and D.J. Carucci Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine Proc Natl Acad Sci USA 98 19 2001 10817 10822
26. J. Schneider, S.C. Gilbert, T.J. Blanchard, T. Hanke, K.J. Robson, and C.M. Hannan Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara Nat Med 4 4 1998 397 402